Colorectal Liver Metastases Clinical Trial
Official title:
Prospective Comparison of 3T Gd-EOB-DTPA-enhanced MRI, Diffusion Weighted MR Imaging and MDCT of Colorectal Liver Metastases for Preoperative Detection and Assessment of Treatment Response Following Chemotherapy Treatment
Verified date | January 2015 |
Source | University Health Network, Toronto |
Contact | n/a |
Is FDA regulated | No |
Health authority | Canada: Ethics Review Committee |
Study type | Interventional |
1. Primovist-enhanced Magnetic resonance imaging (MRI) and Diffusion Weighted MRI (DW-MRI)
is superior to Multidetector Computed axial Tomography (MDCT) in the detection of
colorectal liver metastases. Fatty changes in the liver after chemotherapy treatment
likely reduces the chances of seeing metastatic lesions on CT especially when the
lesions are small (<10 mm). When compared with CT, Primovist-enhanced MRI and DW-MRI
have the potential to provide higher contrast resolution enabling better detection of
colorectal liver metastases following chemotherapy.
2. Primovist-enhanced MRI and DW-MRI are superior to CT in assessing and predicting
treatment response of patients with colorectal liver metastases to chemotherapy.
Primovist-enhanced MRI by providing superior resolution may provide improved accuracy
in metastatic lesion margin detection thereby providing higher accuracy in estimating
tumor response based on size criteria. DW-MRI provides information indirectly about
tumor composition and therefore is likely to be superior to MD-CT in assessing
treatment response.
Two groups of patients will be analyzed. The second group consists of patients with
colorectal liver metastases who are to go for chemotherapy prior to surgery for metastases
resection. This group will be CT and MRI scanned prior to chemotherapy and after
chemotherapy. The first group of patients will consist of those patients who have already
received chemotherapy and are likely to have surgery to resect liver metastases. This group
will have only one set of scans done 4-6 weeks prior to their operation. The pathology of
the resected metastases and CT and MRI images will be analyzed and compared.
Status | Completed |
Enrollment | 50 |
Est. completion date | December 2014 |
Est. primary completion date | July 2014 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Patients with colorectal liver metastases already treated by chemotherapy and scheduled for surgical resection - Patients with colorectal liver metastases scheduled to receive chemotherapy with possibility of future liver resection. Exclusion Criteria: - Acute or Chronic Renal Disease with Estimated GFR (eGFR) <30 mL/min. - Hypersensitivity to MRI contrast or CT contrast or to any ingredient in the formulation or component of the container. - Patients with: acute or chronic severe renal impairment (glomerular filtration rate <30 mL/min/1.73 m2), or acute renal insufficiency of any severity due to the hepato-renal syndrome or in the perioperative liver transplantation period. - General contraindications to MRI such as pacemaker or ferromagnetic implants. - Severe cardiovascular problems - Pregnant or nursing women - Age <18 years - Liver Surgery is not a possibility. |
Allocation: Non-Randomized, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Country | Name | City | State |
---|---|---|---|
Canada | University Health Network-Princess Margaret Hospital | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
University Health Network, Toronto | Bayer |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To establish superiority of Primovist-enhanced liver MRI and DWI to MDCT in the preoperative detection of colorectal liver metastases in patients who have received prior chemotherapy by comparison against pathology or Intra-operative ultrasound. | 18 months | No | |
Secondary | To compare diagnostic performance of MDCT, Diffusion Weighted MR and Primovist-enhanced MRI in the differentiation of viable from non-viable metastatic tumour compared to reference standard of pathology. | 18 months | No | |
Secondary | To investigate in the cohort of patients who have pre and post-chemotherapy MRI the role of DWI in predicting treatment response by baseline pretreatment Apparent Diffusion Coefficient (ADC) values. | 18 months | No | |
Secondary | To assess performance of Primovist-enhanced MRI, DW-MRI and MDCT in assessment of treatment response following chemotherapy in the cohort of patients who have pre and post-chemotherapy MRI. | 18 months | No | |
Secondary | To compare accuracies of Primovist-enhanced MRI and DWI to MDCT in the characterization of non-metastatic liver lesions against histopathology or intra-operative ultrasound. | 18 months | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00779272 -
Impact of Preoperative Chemotherapy on Complications and Regeneration After Resection of Colorectal Liver Metastases
|
N/A | |
Active, not recruiting |
NCT00797251 -
Anatomical Right Posterior Sectionectomy of the Liver by IOUS-Guided Finger Compression
|
N/A | |
Recruiting |
NCT06045286 -
High- and Low-dose Radiotherapy Combined With PD-1 Inhibitors for MSS CRLM
|
Phase 1 | |
Recruiting |
NCT04870879 -
Colorectal Metastasis and Liver Transplantation With Organs From Deceased Donors
|
N/A | |
Completed |
NCT01799044 -
Pilot-study: Non-thermal Ablation Using Irreversible Electroporation to Treat Colorectal Liver Metastases
|
Phase 1 | |
Terminated |
NCT00508872 -
Folfox-B Study for Patients With Colorectal Liver Metastases
|
Phase 2 | |
Recruiting |
NCT05877001 -
The Safety and Efficacy of HAIC+Tislelizumab+Regorafenib in Patients With Colorectal Liver Metastases
|
Phase 2 | |
Completed |
NCT02082782 -
Efficacy of Irreversible Electroporation (IRE) for Central Colorectal Liver Metastases
|
Phase 2 | |
Completed |
NCT00942292 -
The Effect of Fish Oils on Human Hepatic Colorectal Metastases
|
Phase 2 | |
Recruiting |
NCT01191632 -
Effect of Neoadjuvant Radiation on Tumor Infiltrating T-cells by Low Dose Radiation in Colorectal Liver Metastases
|
Phase 1/Phase 2 | |
Completed |
NCT00119899 -
Utility of FDG-PET Scan on the Selection of Patients for Resection of Hepatic Colorectal Metastases
|
Phase 3 | |
Completed |
NCT00184834 -
Quality of Life and Liver Metastases
|
N/A | |
Completed |
NCT00557557 -
Safety Study of Oxaliplatin and 5-fluorouracil Followed by FUDR for Unresectable Colorectal Liver Metastases
|
Phase 1 | |
Recruiting |
NCT05468593 -
Patient Outcomes After Hepatic Artery Infusion Pump Placement
|
||
Completed |
NCT02615665 -
Intratumoral CD3+ and NKp46+ Cells in Colorectal Liver Metastases
|
N/A | |
Terminated |
NCT01318447 -
CyberKnife® for Hepatic Metastases From Colorectal Cancer
|
Phase 2 | |
Completed |
NCT00885950 -
Prevention of the Hepatic Sinusoidal Obstruction Syndrome by Means of Anticoagulants
|
N/A | |
Completed |
NCT02331641 -
Multiple Minor Hepatectomies Versus Major or Extended Hepatectomies for Colorectal Liver Metastases.
|
N/A | |
Completed |
NCT00600522 -
Alternative Surgical Policy for Central Liver Tumors
|
N/A | |
Recruiting |
NCT05265169 -
Ablation With Confirmation of Colorectal Liver Metastases (ACCLAIM)
|
N/A |